UBS/CALL/IDORSIA/14.008/0.125/21.06.24 Stock

Warrant

JIDI0U

CH1237791145

Market Closed - Swiss Exchange 11:20:00 2023-07-19 EDT
0.06 ^CHF	+20.00%

1 month	-45.45%
3 months	-70.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/14.008/0.125/21.06.24

Latest news about IDORSIA LTD

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024	05-31	GL
Idorsia : Invitation to the AGM 2024	05-23	PU
Idorsia : Supplement to the invitation to the AGM 2024	05-23	PU
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders	05-23	GL

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	JIDI0U
ISIN	CH1237791145
Date issued	2022-12-12
Strike	14.01 CHF
Maturity	2024-06-21 (19 Days)
Parity	8 : 1
Emission price	0.51 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.85 CHF
Lowest since issue	0.04 CHF

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company